

DAFTAR PUSTAKA

1. Bacci, Gaetano MD*; Ferrari, Stefano MD*; Bertoni, Franco MD**; Picci, Piero MD†; Bacchini, Patrizia MD**; Longhi, Alessandra MD*; Donati, Davide MD‡; Forni, Cristiana RN**; Campanacci, Laura MD‡; Campanacci MM. Histologic Response of High-Grade Nonmetastatic Osteosarcoma... : Clinical Orthopaedics and Related Research. *Clin Orthop Relat Res.* 2001;386:186-196.
2. Pappo A. *Pediatric Bone and Soft Tissue Sarcomas*. Springer; 2006.
3. MCKENNA, ROBERT J.; SCHWINN, CHARLES P.; SOONG, K. Y.; HIGINBOTHAM NL. Sarcomata of the Osteogenic Series (Osteosarcoma, Fibrosarco... : JBJS. *Sarcomata Osteogenic Ser (Osteosarcoma, Fibrosarcoma, Chondrosarcoma, Parosteal Osteogenic Sarcoma, Sarcomata Aris Abnorm Bone) AN Anal 552 CASES.* 1966.
4. What Are the Key Statistics About Osteosarcoma?
5. Cortes EP, Holland JF, Wang JJ, et al. Amputation and Adriamycin in Primary Osteosarcoma. *N Engl J Med.* 1974;291(19):998-1000. doi:10.1056/NEJM197411072911903.
6. Ebeid W, Amin S, Abdelmegid A. Limb salvage management of pathologic fractures of primary malignant bone tumors. *Cancer Control.* 12(1):57-61.
7. Lewis VO. What's New in Musculoskeletal Oncology. *J Bone Jt Surg.* 2007;89(6):1399-1407. doi:10.2106/JBJS.G.00075.
8. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. *J Bone Joint Surg Am.* 1994;76(5):649-656
9. Kamal AF, Widyawarman H, Husodo K, Hutagalung EU, Rajabto W. Clinical Outcome and Survival of Osteosarcoma Patients in Cipto Mangunkusumo Hospital: Limb Salvage Surgery versus Amputation. *Acta Med Indones.* 2016;48(3):175-183.
10. Becker RG, Galia CR, Morini S, Viana CR. Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies. *Acta Ortop Bras.* 2013;21(4):233-238. doi:10.1590/S1413-78522013000400010.
11. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. *Lancet (London, England).* 1998;351(9114):1451-1467.
12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science.* 1987;235(4785):177-182.

13. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. *Cancer*. 2002;94(5):1397-1404.
14. Zhang X, Xu S, Wang D, et al. Over-expression of HER2 promotes cell metastasis and is associated with the prognosis of osteosarcoma. 2016;9(2):1439-1445.
15. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. *Cancer*. 1976;37(1):1-11.
16. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 2007;25(15):1960-1966. doi:10.1200/JCO.2006.07.9525.
17. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nat Med*. 2004;10(2):145-147. doi:10.1038/nm988.
18. Nasional KPK, ed. *Pedoman Nasional Pelayanan Kedokteran Osteosarkoma*.
19. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. *Int J Cancer*. 2009;125(1):229-234. doi:10.1002/ijc.24320.
20. Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. *Cancer*. 1986;57(7):1442-1449.
21. Clark JCM, Dass CR, Choong PFM. A review of clinical and molecular prognostic factors in osteosarcoma. *J Cancer Res Clin Oncol*. 2008;134(3):281-297. doi:10.1007/s00432-007-0330-x.
22. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years. *Tumori*. 90(5):478-484.
23. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. *J Biol Chem*. 2012;287(38):31666-31673. doi:10.1074/jbc.R112.343061.
24. Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. *Indian J Orthop*. 2014;48(3):238-246. doi:10.4103/0019-5413.132491.
25. O'Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. *World J Radiol*. 2015;7(8):202-211. doi:10.4329/wjr.v7.i8.202.
26. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. *J Bone Joint Surg Am*. 1996;78(5):656-663.
27. Nasional KPK. *PNPK Osteosarkoma Kementerian Kesehatan RI*. Jakarta; 2015.

28. Shaikh AB, Li F, Li M, et al. Present advances and future perspectives of molecular targeted therapy for osteosarcoma. *Int J Mol Sci.* 2016;17(4). doi:10.3390/ijms17040506.
29. Salter RB. Textbook of Disorders and Injuries of the Musculoskeletal System: An Introduction to Orthopaedics, Fractures, and Joint Injuries, Rheumatology, Metabolic Bone Disease, and Rehabilitation. In: Lippincott Williams & Wilkins; 1999.
30. Steven P. Meyers. *MRI of Bone and Soft Tissue Tumors and Tumorlike Lesions.* Thieme; 2008.
31. Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T, Yamashita T. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. *J Bone Jt Surg - Br Vol.* 2009;91-B(6):784-788. doi:10.1302/0301-620X.91B6.21853.
32. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. *N Engl J Med.* 2006;355(15):1572-1582. doi:10.1056/NEJMs060185.
33. Cardones AR, Banez LL. VEGF inhibitors in cancer therapy. *Curr Pharm Des.* 2006;12(3):387-394. \
34. Geller DS, Gorlick R. HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies. *Expert Opin Pharmacother.* 2010;11(1):51-61. doi:10.1517/14656560903419614.
35. Bakhshi S, Gupta A, Sharma MC, Khan SA, Rastogi S. Her-2/neu, P-53, and Their Coexpression in Osteosarcoma. *J Pediatr Hematol Oncol.* 2009;31(4):245-251. doi:10.1097/MPH.0b013e318197947e.
36. Li Y, Zhang N. Association between HER-2 over-expression and prognosis in human osteosarcoma: a meta-analysis. *Chinese J Clin Oncol.* 2008;5(5):367-372. doi:10.1007/s11805-008-0367-x.
37. Zhao D, Jia P, Wang W, Zhang G. VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma. *Mol Cell Biochem.* 2015;400(1-2):87-95. doi:10.1007/s11010-014-2265-2.
38. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. *J Pediatr Hematol Oncol.* 2003;25(1):27-32. \
39. Kansara M, Thomas DM. Molecular Pathogenesis of Osteosarcoma. *DNA Cell Biol.* 2007;26(1):1-18. doi:10.1089/dna.2006.0505.
40. Lamplot JD, Denduluri S, Qin J, et al. The Current and Future Therapies for Human Osteosarcoma. *Curr Cancer Ther Rev.* 2013;9(1):55-77. doi:10.2174/1573394711309010006.

41. Baptista AM, Camargo AFDF, Filippi RZ, Oliveira CRGCM De, Azevedo Neto RS De, Camargo OP De. Correlation between the expression of vegf and survival in osteosarcoma. *Acta Ortopédica Bras.* 2014;22(5):250-255. doi:10.1590/1413-78522014220500978.
42. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science.* 1985;229(4717):976-978.
43. Hughes DPM, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. *Cancer Res.* 2004;64(6):2047-2053.
44. Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. *Mol Ther.* 2009;17(10):1779-1787. doi:10.1038/mt.2009.133.
45. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. *Clin Adv Hematol Oncol.* 2010;8(10):705-718.
46. Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. *Cancer.* 2001;92(3):677-683.
47. Lampli J, Fan M, Rosenthal HG, et al. Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. *Int Orthop.* 2012;36(11):2307-2313. doi:10.1007/s00264-012-1629-z.
48. Peng N, Gao S, Guo X, et al. Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway. *Am J Transl Res.* 2016;8(2):1005-1015.
49. Kang KS, Song KS, Lee JS, Yang JJ, Song IS. Comparison of radiographic and computed tomographic measurement of pedicle and vertebral body dimensions in Koreans: The ratio of pedicle transverse diameter to vertebral body transverse diameter. *Eur Spine J.* 2011;20(3):414-421. doi:10.1007/s00586-010-1560-1.
50. Lin F, Zheng S, Shen Z, et al. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. *Med Oncol.* 2011;28(2):649-653. doi:10.1007/s12032-010-9493-4.
51. Endo-Munoz L, Cai N, Cumming A, et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. *PLoS One.* 2015;10(8):e0133592. doi:10.1371/journal.pone.0133592.



UNIVERSITAS
GADJAH MADA

**HUBUNGAN EKSPRESI VEGF DAN HER-2 DENGAN PROFIL KLINIS, PARAMETER LABORATORIUM
DAN TINGKAT**

KELANGSUNGAN HIDUP PADA PASIEN OSTEOSARKOMA DI RSUP DR SARDJITO

YUNI ARTHA PRABOWO, Prof. Dr. Armis, Sp.B, Sp.OT(K), FICS

Universitas Gadjah Mada, 2017 | Diunduh dari <http://etd.repository.ugm.ac.id/>